The UK National Institute for
Health and Care Excellence (NICE)
has given the go ahead for afatinib
(Giotrif from Boehringer Ingelheim)
indicated for lung cancer to be paid
for by the NHS, and people newly
diagnosed with the blood cancer
multiple myeloma would now be
guaranteed access to Bortezomib
(Velcade by Janssen).The above article was sent to subscribers in Pharmacy Daily's issue from 24 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Apr 14
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.